Thus, this study provides new insights into the mechanisms through which EMT is regulated in residual HCC after insufficient RFA and suggests FLOT1 and FLOT2 as potential targets for anti-metastatic therapy. The gene discussed is FLOT1; the disease is hepatocellular carcinoma.